Article
Open Access
Volume 4 · Issue 4 · 2024
pp. 228–234
Monoclonal Gammopathy of Undetermined Significance is Not Associated with Renal Cell Carcinoma
Deniz Yılmaz1 
, Ezgi Şahin2 , Emine Gültürk3 , Serdar Karadağ4
, Ezgi Şahin2 , Emine Gültürk3 , Serdar Karadağ4
1
Department of Internal Diseases, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Türkiye
2
Department of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Türkiye
3
Department of Hematology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye
4
Department of Urology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye
Abstract
Objectives: The aim of this study was to investigate monoclonal gammopathy of undetermined significance (MGUS) in patients with renal cell carcinoma (RCC) and compare to healthy individuals.
Methods: This was a case-control study conducted between July 2022 and December 2022 including 68 patients with RCC and 47 healthy controls.
Results: The median age of control group was 67 (51-75) years and that of the RCC group was 59 (51-69.5) (p=0.039). Sex distributions were similar in the two groups. RCC disease duration was 24 (12-60) months. The albumin, calcium, hemoglobin, hematocrit levels, and lymphocyte (p<0.001 for all) and platelet counts (p=0.017) were significantly higher in the RCC group compared to controls. There was no significant difference between the groups in terms of the number of the patients with MGUS (p=0.512), monoclonal band positivity (p=0.512), abnormal bands positivity (p=0.080) and median gammaglobulin level (p=0.774).
Conclusion: The present study shows no evidence for increased MGUS incidence in patients with RCC; however, more comprehensive studies are required to clarify these findings in different populations and determine the potential roles of other factors in the relationship between RCC and MGUS.
Methods: This was a case-control study conducted between July 2022 and December 2022 including 68 patients with RCC and 47 healthy controls.
Results: The median age of control group was 67 (51-75) years and that of the RCC group was 59 (51-69.5) (p=0.039). Sex distributions were similar in the two groups. RCC disease duration was 24 (12-60) months. The albumin, calcium, hemoglobin, hematocrit levels, and lymphocyte (p<0.001 for all) and platelet counts (p=0.017) were significantly higher in the RCC group compared to controls. There was no significant difference between the groups in terms of the number of the patients with MGUS (p=0.512), monoclonal band positivity (p=0.512), abnormal bands positivity (p=0.080) and median gammaglobulin level (p=0.774).
Conclusion: The present study shows no evidence for increased MGUS incidence in patients with RCC; however, more comprehensive studies are required to clarify these findings in different populations and determine the potential roles of other factors in the relationship between RCC and MGUS.
Keywords: Renal cell carcinoma, monoclonal gammopathy of undetermined significance, immunofixation, protein, electrophoresis
Current Issue Vol 4 · Iss 4
